AUTL

0.90887.23%
MP

Martin Pule

Founder, Senior VP & Chief Scientific Officer

Dr. Martin Pule, MBBS, MD., is the Founder, Senior Vice President and Chief Scientific Officer of Autolus Therapeutics Plc. since August 2014 and served as its Director from August 2014 to June 21, 2018. Dr. Pule founded Autolus Limited in 2014 and serves as its Chief Scientific Officer. He is Clinical Senior Lecturer in the Dept. of Haematology at UCL Cancer Institute since 2010 and Honorary Consultant in Haematology at University College London Hospital since 2010. His research is focused on many aspects of genetic engineering of T-cells for cancer treatment, with a particular focus on CARs. He entered the T-cell engineering field in 2001 as a traveling Fulbright Scholar at the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston. Dr. Pule was the first to describe third generation forms of CARs and described one of the first clinical studies of CARS, which showed efficacy in a solid cancer. He serves as Director of the UCL Chimeric Antigen Receptor (CAR) programme. He served as a Member of Scientific Advisory Board at MANA Therapeutics, Inc., until March 2023. Dr. Pule holds a Bachelor of Medicine and Bachelor of Surgery from University College Dublin and is a Fellow of the Royal College of Pathologists.

Positions